Results from the PRO-TECT randomized controlled trial, conducted in 52 community oncology practices was recently published in JAMA. The purpose of PRO-TECT was to "determine whether electronic monitoring of symptoms by patients undergoing treatment for metastatic cancer improves survival, quality of life outcomes and other outcomes compared with usual care." Following enrollment of 1191 adult metastatic cancer patients, patients in the PRO group "had significantly greater odds of experiencing clinical meaningful benefits versus usual care for physical function", with an improvement of at least 5 points in 7.7% of patients studied.
To read more about the PRO-TECT trial, click here.
Source mentioned: Basch E, Schrag D, Henson S, et al. Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer A Randomized Clinical Trial. JAMA 2022;327(24):2413-2422.
No comments:
Post a Comment